Draft Genetic Testing Policies

Blue Cross and Blue Shield of Florida partners with AIM Specialty Health® to administer genetic testing solutions for our members.

AIM is our business associate and is an independent company that provides diagnostic testing, information and services. AIM has agreed to follow our privacy and security policies regarding the confidentiality and protection of personal health information.


Note: Coverage is subject to member's specific benefits. Group-specific policies will supersede these policies when applicable. Please refer to member's benefit plan.

Draft Genetic Testing Policies

Effective for dates of service on and after March 11, 2023, the changes in the document below will apply to the AIM Genetic Testing Clinical Appropriateness Guidelines. Part of AIM's semi-annual review process, these updates are focused on advancing efforts to drive clinically appropriate, safe and affordable healthcare services.

Summary of Changes to AIM Genetic Testing Clinical Appropriateness Guidelines Effective March 11, 2023

To continue to the AIM Specialty Health website to view genetic testing policies, click "Accept” below.


Comment on Draft Policies

To ensure that the development of medical policies occurs through an open, collaborative process, we welcome comments about medical policies that are in the draft stage. 

Participating providers are invited to submit scientific, evidence-based information, professional consensus opinions and other information supported by medical literature relevant to these draft policies for consideration.

Comments are accepted for 45 days from the posting date listed on the draft

Make sure your voice is heard by providing feedback directly to us:

1. Complete our medical policy feedback form

2. Or send comments by mail or fax to:

Birmingham Service Center
Attn: Health Management - Medical Policy
P.O. Box 10527
Birmingham, AL 35202

Fax: 205-220-0878